Cancer market commentary: Roche’s Tecentriq muscles into NSCLCRoche’s PD-L1 drug has generated impressive data in second line lung cancer Share XCancer market commentary: Roche’s Tecentriq muscles into NSCLChttps://pharmaphorum.com/esmo-2016/cancer-market-commentary-roches-tecentriq-muscles-nsclc/